TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at the initiation of anti-epileptic drug (AED) treatment as noted in the database~* A record of at least one medical visit with a diagnosis of epilepsy (ICD-9-CM 345.xx) or at least two diagnoses of non-febrile convulsions (ICD-9-CM 780.30 or 780.39) occuring more than 30 days apart~* At least one pharmacy claim for an anti-epileptic drug (AED)~* Continuous enrollment throughout the observation period (minimum of 365 days). Patients with gaps in Medicaid enrollment will be observed only during their period of continuous enrollment, provided that all the above criteria are met~Exclusion Criteria:~* Age less than 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medicaid patients with uncontrolled epilepsy (Type: None): Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
- Medicaid patients with well-controlled epilepsy (Type: None): Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
- Medicaid patients with intermediate epilepsy (Type: None): Database records for patients who are not classified as uncontrolled or well-controlled
- Patients in a private health plan with uncontrolled epilepsy (Type: None): Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
- Patients in a private health plan with well-controlled epileps (Type: None): Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
- Patients in a private health plan with intermediate epilepsy (Type: None): Database records for patients who are not classified as uncontrolled or well-controlled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Low Dose Naltrexone in Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.~Exclusion Criteria:~Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Naltrexone first (Type: EXPERIMENTAL): LDN first, then placebo.
- Placebo - sugar pill first (Type: PLACEBO_COMPARATOR): Placebo first, then LDN.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects should be diagnosed with acne vulgaris of the face~* Fitzpatrick skin types I-III (due to lack of safety data for the investigational product in darker skin types)~* Disease severity and total lesion count should be similar in both TAs~* Disease severity grade as moderate to severe according to the investigator's global assessment (grade 3-4)~* Age 18 to 35 years incl.~* Male or female~* Female Subjects must be of either non-childbearing potential or child-bearing potential with a confirmed negative pregnancy test~Exclusion Criteria:~* Subjects with nodulocystic acne, acne conglobata, acne fulminans, secondary acne (e.g. chlor-acne, drug-induced acne)~* Subjects with previous history of keloid formation or post-inflammatory hyperpigmentation~* Systemic retinoids within 12 month or systemic antibiotics within 1 month before Day 1~* Topical retinoids within 3 months before Day 1 or other topical treatments and/or medicated products and cosmetics that in the opinion of the investigator may influence the subjects acne vulgaris (including soaps containing antibacterial agents such as benzoyl peroxide, keratinolytic agents such as salicylic acid, skin fresheners/astringents or aftershave products) within 1 month before Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- LEO43204 0,018% (Type: EXPERIMENTAL): Experimental drug
- Vehicle (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All adult patient referred for colonoscopy to AIG~2. Age 18 - 75 years old~Exclusion Criteria:~1. Acute GI bleeding.~2. Patient of bowel preparation regime other than excepted for the study.~3. Renal insufficiency.~4. Dementia.~5. Symptomatic heart failure.~6. Recent Myocardial Infarction.~7. Patients with ileus.~8. Suspected bowel obstruction.~9. Prior alimentary tract surgery.~10. Significant gastroparesis.~11. Gastric outlet obstruction.~12. Toxic colitis or megacolon.~13. Pregnant or lactating patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Lubiprostone (Type: EXPERIMENTAL): Lubiprostone with PEG solution versus Placebo with PEG solution
- lubiprostone versus placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, women aged 18 to 49 years.~* History of severe PMS symptoms over the last year, as determined by the investigator.~* Regular 21 to 35 day menstrual cycle for 2 months prior to first study visit.~Exclusion Criteria:~* Major depressive disorder requiring antidepressant treatment or hospitalization within the last 3 years.~* Contraindication to combination oral contraceptives.~* Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.~Other exclusions apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 38-46; BMI 18.5-24.0kg/m2; intended to undergo PGT-A; GnRH Antagonist protocol for ovarian stimulation; normal semen analysis for the male partner~Exclusion Criteria:~* Endometriosis grade 3 or higher, untreat hydrosalpinx;~* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex);~* Untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)~* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;~* Women who received other supplement drugs during ovarian stimulation

- Gender: FEMALE
- Minimum Age: 38 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- GH group (Type: EXPERIMENTAL): Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
- Control group (Type: ACTIVE_COMPARATOR): No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women gestational age less than 36 weeks with heartburn~Exclusion Criteria:~* Having medical disease that contraindicated to use study drug~* Allergic to alginate-based reflux suppressant and magnesium-aluminium antacid gel

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Alginate-based reflux suppressant (Type: ACTIVE_COMPARATOR): Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
- magnesium-aluminium antacid gel (Type: SHAM_COMPARATOR): magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic heart failure and implantation of cardiac resynchronization therapy more than 6 months ago and presence of iron deficiency (ferritin \< 100 μg/l, irrespective of TSAT or ferritine between 100 - 300 μg/l with TSAT \< 20%) and presence of incomplete reverse remodeling (LVEF \< 40%).~2. Age ≥18 years~3. Obtained informed consent~4. Stable pharmacological therapy of heart failure during the last 4 weeks (with the exception of diuretics)~Exclusion Criteria:~1. Hemochromatosis, iron overload, defined as TSAT \> 45%~2. Hemoglobin \> 15 g/dl at inclusion~3. Known hypersensitivity to injectafer®.~4. Known active infection, CRP\>20 mg/L, clinically significant bleeding, active malignancy.~5. Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range.~6. Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).~7. History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.~8. Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.~9. Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke within the last 3 months.~10. Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.~11. Inability to fully comprehend and/or perform study procedures in the investigator's opinion.~12. Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening is possible after substitution therapy).~13. Pregnancy or lactation.~14. Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.~15. Planned cardiac hospitalization during study follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ferric carboxymaltose (Type: EXPERIMENTAL): Ferric carboxymaltose according to SmPC
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline (0.9%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* House dust mite-induced allergic rhinitis/mild intermittent asthma~Exclusion Criteria:~* Use of previous allergy immunotherapy for house dust mite asthma~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Low dose SLIT (Type: ACTIVE_COMPARATOR): Low dose SLIT
- High dose SLIT (Type: ACTIVE_COMPARATOR): High dose SLIT
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years of age or older.~* Written informed consent and written authorization for use or release of health and research study information have been obtained.~* Subject has chronic Prosthetic knee joint pain for more than 3 months.~* Subject has pain 6 or greater on a 10 point Numerical Pain Rating scale~* Ability to follow study instructions and likely to complete all required visits.~* Negative urine pregnancy test on the day of treatment prior to the administration of study medication (for females of childbearing potential). (if applicable)~* Negative infectious etiology workup (joint aspiration, serological parameters such as Erythrocyte Sedimentation Rate (ESR) or C-reactive protein (CRP) and clinical examination).~* Patients who were considered not to be candidates for Prosthetic knee joint revision surgery and have failed traditional treatments including oral pain medications, as determined by referring orthopedic surgeon~Exclusion Criteria:~* Use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function.~* Any medical condition that may put the subject at increased risk with exposure to BOTOX ®including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or known disorders of neuromuscular function~* Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.~* Know allergy or sensitivity to any of the components in the study medication.~* History of recent or ongoing alcohol or drug abuse.~* Known, uncontrolled systemic disease.~* Concurrent participation in another research study~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.~* Patients whose pain is rated as less than 6 on a 10 point Numerical Pain Rating scale at the screening visit

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
- B (Type: PLACEBO_COMPARATOR): Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable COPD (Stage II or Stage III) according to the current GOLD Guidelines (GOLD 2010).~* Patients with a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥ 30% and \< 80% of the predicted normal, and a post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.70 at screening~* Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack/day x 10 yrs, or ½ pack/day x 20 yrs).~* Symptomatic patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3.~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Patients who, in the judgment of the investigator, or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition before Visit 1.~* Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. (BPH patients who are stable on treatment can be considered).~* Patients receiving medications in the classes listed in the protocol as prohibited.~Other protocol-defined inclusion/exclusion criteria apply and can be found in the study protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 (Type: EXPERIMENTAL): NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-treated or treatment naive patients with gonadotropin-dependent precocious puberty~* Pre-treatment pubertal type response of LH to a stndard GnRH stimulation test before initiation of treatment~Exclusion Criteria:~* Children who are less than 2 years of age at enrollment~* Children whose chronological age is greater than 8 years (naive) and 10 years (pre-treated) for girls or 9 years (naive) and 11 years (pre-treated) for boys at the onset of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Histrelin Subcutaneous Implant (50 mg) (Type: EXPERIMENTAL): Subcutaneous implant designed to deliver histrelin continously for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic renal failure with an estimated glomerular filtration rate \< 60 milliliter per minute per 1.73m\^2 and not expected to begin dialysis for at least 12 weeks.~2. Two consecutive hemoglobin values ≥ 8.0 g/dL and \< 11.0 g/dL within 4 weeks prior to randomization.~Exclusion Criteria:~1. Females who are pregnant or breast-feeding.~2. Treatment with an ESA in the 12 weeks prior to randomization.~3. Known intolerance to any ESA, parenteral iron supplementation, or pegylated molecule.~4. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.~5. Known bleeding or coagulation disorder.~6. Known hematologic disease or cause of anemia other than renal disease~7. Poorly controlled hypertension~8. Evidence of active malignancy within one year prior to randomization.~9. A scheduled kidney transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide 0.025 mg/kg (Type: EXPERIMENTAL): None
- Peginesatide 0.04 mg/kg (Type: EXPERIMENTAL): None
- Darbepoetin Alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete